Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharmaceutical companies like Aquestive Therapeutics produce SEC filings containing critical information about drug development progress, regulatory interactions, and commercial performance that doesn't appear in press releases. The 10-K annual report details clinical trial status, FDA correspondence, intellectual property positions, and revenue breakdowns by product. For biotech investors, these disclosures reveal pipeline advancement, regulatory risks, and commercialization challenges.
Aquestive's 10-Q quarterly filings track product sales trends, research spending, and cash runway between major announcements. The Management Discussion section explains how approved products perform commercially, what development milestones lie ahead, and where the company allocates resources across its PharmFilm platform. Form 8-K filings disclose material events immediately, including FDA decisions, partnership agreements, financing transactions, and clinical trial results before they reach mainstream news.
Form 4 insider transaction filings show when executives and directors buy or sell Aquestive shares, potentially signaling confidence in upcoming clinical data or concerns about development setbacks. The annual proxy statement (DEF 14A) details executive compensation structures, revealing how leadership incentives align with clinical and commercial milestones. Our AI-powered summaries identify key disclosures across these documents, highlighting regulatory correspondence, trial outcomes, and financial metrics that matter for evaluating specialty pharmaceutical investments.
Access comprehensive SEC filings for Aquestive Therapeutics, with AI assistance that extracts critical information about FDA interactions, pipeline progress, and commercial execution. Track Form 4 transactions, review quarterly 10-Q results, and analyze annual 10-K disclosures without reading hundreds of pages of technical documentation.
Aquestive Therapeutics (AQST) reported an insider equity award to its Chief Development Officer. On 11/10/2025, the officer acquired 50,000 shares of Common Stock at $0, described as restricted stock that vests over three annual installments (25%, 25%, 50%). The filing also shows a non-qualified stock option for 50,000 shares at an exercise price of $5.58, granted on 11/10/2025 and expiring on 11/10/2035, with the same 25/25/50 vesting schedule.
Aquestive Therapeutics (AQST) reported an insider ownership update. An officer serving as Chief Development Officer filed a Form 3 pursuant to Section 16(a). The filing indicates it was filed by one reporting person and lists the date of event as 11/03/2025. In the remarks, the filer states: No securities are beneficially owned. The document is signed by /s/ Lori Braender, as Attorney-In-Fact on behalf of the reporting person.
Aquestive Therapeutics (AQST) furnished an investor presentation via Form 8-K. The company provided Q3 Earnings Supplemental Materials as Exhibit 99.1 under Item 7.01 (Regulation FD) on November 6, 2025. The materials are incorporated by reference into Item 7.01 and are posted on the Investors section of its website.
The company stated that the information in Item 7.01 (including Exhibit 99.1) is furnished, not filed, and is not subject to Section 18 liabilities or automatically incorporated into Securities Act or Exchange Act filings.
Aquestive Therapeutics reported Q3 2025 results, showing revenue of $12.8 million and a net loss of $15.4 million. Year-to-date revenue was $31.5 million with a net loss of $51.9 million as the company continued to invest in R&D and commercialization.
Cash and cash equivalents were $129.1 million as of September 30, 2025. The capital position was bolstered by a public offering completed on August 14, 2025 for 21.25 million shares at $4.00 per share, generating $79.9 million in net proceeds, and by 7.46 million shares sold under the ATM program year-to-date for $21.3 million in net proceeds. Shares outstanding were 121,658,113 at quarter-end and 122,003,113 as of November 3, 2025.
Manufacture and supply revenue rose year over year in Q3 to $11.5 million, while license and royalty revenue declined due to prior year one-time deferred revenue recognition. Selling, general and administrative expenses increased to $15.3 million in the quarter. Customer concentration remained high, with Indivior representing approximately 72% of nine-month 2025 revenue and Hypera 18%.
The company also disclosed an August 13, 2025 agreement with funds managed by RTW Investments LP for a $75.0 million purchase price tied to FDA approval of Anaphylm and other conditions, with tiered U.S. revenue-share payments capped at $187.5 million by December 31, 2035 or $225.0 million thereafter.
Aquestive Therapeutics (AQST) furnished an 8-K announcing its third-quarter 2025 financial results and recent business updates. The company attached a press release and financial schedules as Exhibit 99.1 and provided an investor presentation as Exhibit 99.2.
The materials are furnished, not filed, under Items 2.02 and 7.01. The investor presentation is also available on the company’s website under Investors > Events and Presentations.
Aquestive Therapeutics (AQST) Chief Operating Officer reported transactions on 10/15/2025. The officer exercised 25,000 non-qualified stock options at a $3.1027 exercise price (code M) and sold 67,575 shares at an average price of $7.01 (code S), pursuant to a Rule 10b5-1 trading plan.
Following the transactions, the officer beneficially owned 240,771 shares directly and 2,000 shares indirectly by spouse. The reported option, granted on June 10, 2021, is fully vested and shows 0 derivative securities remaining after the exercise.
Aquestive Therapeutics (AQST) reported an insider transaction: the Chief Medical Officer sold 20,272 shares of common stock on 10/15/2025 at a weighted average price of $7.00, with individual trades ranging from $7.00 to $7.02, executed under a Rule 10b5-1 trading plan.
After the transaction, the reporting person beneficially owned 282,475 shares, held directly.
Aquestive Therapeutics (AQST) reported an insider transaction on a Form 4. An officer sold 10,000 shares of common stock at $7 on 10/15/2025, reported with transaction code S.
The filing states the sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Following the transaction, the reporting person beneficially owns 268,323 shares, held directly. The officer’s title is SVP IT, HR, & Communications.
FAQ
What is the current stock price of Aquestive Therapeutics (AQST)?
What is the market cap of Aquestive Therapeutics (AQST)?
